Pharma Industrial India - Professional magazine for pharma industry suppliers and lab technology

NEWS ABOUT >

Biotechnology

Clean Rooms

Clinical Trials

Consultants

Digitalization

Drug Discovery & Development

Engineering

Global Pharma

Industrial talks

Ingredients

Lab Equipment

Logistics & Distribution

Manufacturing

Market

Outsourcing

Packaging

Quality / GMP

Regulation

Safety

Last edition

All magazines
Subscribe to our magazine

News about "NLRP3 inflammasome inhibitors"

Olatec Therapeutics Presents Promising Preclinical Data for Dapansutrile in Parkinson's Disease at MJFF Forum

Olatec Therapeutics presented MJFF-funded preclinical data showing its oral NLRP3 inhibitor dapansutrile delivered disease-modifying effects across two translational Parkinson’s disease mouse models.

NLRP3 Inflammasome Inhibitors | 21/01/2026 | By News Bureau | 232

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members